Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Future Directions for Treating Advanced Ovarian Cancers

January 20th 2017

Ongoing PARP Inhibitor Research in Ovarian Cancer

January 20th 2017

Differences Among PARP Inhibitors in Ovarian Cancer

January 20th 2017

Sequencing Therapies for Ovarian Cancer

January 20th 2017

Niraparib Maintenance Therapy for Ovarian Cancer

January 20th 2017

Rucaparib for Ovarian Cancer

January 20th 2017

PARP Inhibitors for Ovarian Cancer: Use of Olaparib

January 20th 2017

Bevacizumab for Recurrent Ovarian Cancer

January 20th 2017

Recurrent Ovarian Cancer; Considerations Beyond the Platinum-Free Interval

January 20th 2017

Dose-Dense Chemotherapy for Ovarian Cancer; Adding Bevacizumab

January 20th 2017

Intravenous vs Intraperitoneal Chemotherapy for Ovarian Cancer

January 20th 2017

Surgical Management of Advanced Ovarian Cancer

January 20th 2017

When to Refer to Genetic Counseling

January 20th 2017

BRCA Testing for Ovarian Cancer

January 20th 2017

Classification of Ovarian Cancers

January 20th 2017

Dr. Markman on Combination Treatments in Ovarian Cancer

January 19th 2017

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses combination treatments in ovarian cancer.

Dr. Kristeleit on the Safety Profile of Rucaparib in Ovarian Cancer

January 18th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the safety profile of rucaparib in the treatment of patients with ovarian cancer.

Dr. Markman on Immune Targeting in Ovarian Cancer

January 14th 2017

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the development of immune targeting in ovarian cancer.

Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian Cancer

January 10th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

Dr. Muggia on Challenges in Ovarian Cancer Treatment

January 6th 2017

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses the current challenges oncologists are facing in the treatment landscape of ovarian cancer.